CYLD expression in dendritic cells involved in the immunoregulation of pulmonary adenocarcinoma via NF-κB pathway

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Interleukin-33 (IL33) previously showed tumor-repressive effects in pulmonary adenocarcinoma (PA) through dendritic cell (DC) regulation.
• The precise molecular mechanisms by which DCs influence PA remain incompletely understood.

Purpose of the Study:

• To elucidate the role of CYLD in the context of PA.
• To investigate the molecular mechanisms by which CYLD-deficient DCs impact PA progression and T cell responses.

Main Methods:

• Utilized CYLD knockout (CYLD^-/-) mouse models to assess PA survival rates.
• Examined the expression and nuclear translocation of NF-κB signaling in CYLD-deficient DCs.
• Investigated the effects of inhibiting the NF-κB pathway on DC-mediated T cell proliferation and function.

Main Results:

• CYLD^-/- mice exhibited reduced survival rates in PA models.
• Knockout of CYLD in DCs suppressed PA progression in mice.
• CYLD deficiency in DCs led to decreased NF-κB signaling and nuclear translocation.
• Inhibition of the NF-κB pathway impaired DC-induced proliferation and function of CD4⁺ T cells.

Conclusions:

• CYLD functions as a tumor suppressor in PA by modulating DC activity through the NF-κB signaling pathway.
• CYLD deficiency in DCs negatively impacts T cell responses crucial for anti-tumor immunity.
• CYLD represents a potential therapeutic target for enhancing immunotherapy in PA.